Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
308
Total raised
£4.1B
disclosed amounts
This month
£27.8M
raised so far
The Series A round will fund the continued development of the company platform for hard-to-drug targets.
"We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery."
The funding round was led by Archangels to support human trials of the BioCaptis device.
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
The financing round was co-led by Lansdowne Partners, Oxford Science Enterprises, and Parkwalk Advisors.
"Global agriculture needs a new Green Revolution if we are to feed the world sustainably. Being able to control weeds is critical to both yield and the cost of production in most crops and new herbicide modes of action are essential. It’s very exciting to see moa starting to play its part in this new revolution by advancing so far in such little time."
The funding round was led by DSW Ventures to help expand manufacturing and commercial teams.
"This new partnership will enable us to build with confidence upon the foundation provided by Aston University and Innovate UK to commericalise iDPC at scale and to accelerate the development of innovative medicines."
The Series A round will fund expansion across the United States and Europe for the cultural preservation platform.
"We believe that collecting organisations should have access to cost-effective technology to help conserve our shared cultural legacy. COVID-19 has hastened a shift in an organization's expectations for cost-effective, remote-accessible solutions. We want to give an amazing experience for managing the data that drives preservation outcomes to all collecting organisations, regardless of size or location."
